With a $33 million series B round now under his belt, Glycomine Inc.'s CEO said serendipity is a large part of what brought the company to study glycosylation disorders, a rare disease that affects about 1,000 people.
Neoleukin Therapeutics Inc. and Aquinox Pharmaceuticals Inc. agreed to a merger in which Aquinox acquires Neoleukin, and Neoleukin becomes the official company name. The combined company plans to develop and commercialize computationally designed protein therapeutics for unmet needs in immuno-oncology, inflammation and autoimmunity.
Aveo Oncology Inc. and Kyowa Kirin Co. Ltd. amended their 2006 license agreement so that Kyowa Kirin can buy back the non-oncology rights of tivozanib in Aveo territories, including the U.S. and the EU, while Aveo retains U.S. rights in cancer.
No day is a good one for a company connected to a failed phase III trial, but Monday's hammering of Glycomimetics Inc. (NASDAQ:GLYC) shares was particularly tough as the greater market's weakness provided no shelter.
Poor second-quarter sales of newly launched Inbrija, the first and only inhaled levodopa, pummeled Acorda Therapeutics Inc. (NASDAQ:ACOR) as the stock lost nearly half its value, 48.9%, on Friday.
Aveo Oncology Inc. and Kyowa Kirin Co. Ltd. amended their 2006 license agreement so that Kyowa Kirin can buy back the non-oncology rights of tivozanib in Aveo territories, including the U.S. and the EU, while Aveo retains U.S. rights in cancer.
Achieving statistically significant improvement over placebo with JAK inhibitor ATI-501 didn't satisfy Aclaris Therapeutics Inc.'s shareholders as the stock (NASDAQ:ACRS) dramatically dropped 26.4% on Wednesday.
The failure of Novartis AG's Entresto in a phase III clinical trial staggered the stock (NASDAQ:NVS) somewhat Monday, down just 1.14%, but the real trauma may well be the loss of roughly $2.5 billion in anticipated sales.
Ending the $2.6 billion agreement from 2016 with Celgene Corp. lifted the fortunes of Jounce Therapeutics Inc. (NASDAQ:JNCE) Wednesday as the stock rose 10.5%. Three years ago, Jounce and Celgene's massive deal was seen as a win for both. Jounce was to receive a $225 million up-front payment and a $36 million equity investment as part of a five-candidate immuno-oncology collaboration.
David Southwell, a seasoned pharma exec and CEO of newly funded Tscan Therapeutics Inc., called from a small, unadorned conference room on the Harvard campus to talk about his new company. He's used to being on the clinical development side, where the accommodations are a bit more posh, but nonetheless he's pleased to be investigating T-cell therapy for cancer patients.
